FACE-OFF: Team Blue vs Team Purple : Episode 5
Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?
Panelists discuss how to approach patients who show inadequate response to initial erythropoiesis-stimulating agent (ESA) therapy, including assessment strategies and potential next steps in treatment modification.
CN24_FO_MDS_Seg05_ESA
Video Player is loading.
EP: 1.COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial
EP: 2.MEDALIST and IMerge Trial Presentation and Discussion
EP: 3.Debate: Do We Treat First With ESAs or With Luspatercept?
EP: 4.Do We Start Luspatercept at the Highest Dose and Titrate Down or Start Low and Titrate Up?
Now Viewing
EP: 5.Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?
EP: 6.Clinical Scenario: How Do We Treat Patients With Ring Sideroblast/Genetic Abnormalities?
Recent Videos
Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
Patient Selection and Timing Considerations for CAR T Therapy
Long-Term Efficacy and Real-World Outcomes With Liso-cel
Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA
Understanding Janet's Journey: Navigating HER2+ Metastatic Breast Cancer & Treatment Options
Related Content
